Medical Devices Japan

Japan Sepsis Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Sepsis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Biomarker, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $55.7 Mn Placeholder estimate
Estimate 2025 $61.1 Mn 5.7% of the global market
Projected 2034 $140.6 Mn 130.1% Adds $79.5 Mn over 9 forecast years
CAGR 2025–2034 9.7% Faster than 55% of 173 Medical Devices markets here
Key players 5
  • Japan is 5.72% of the global market.
  • In APAC, the largest is China at $82.4 Mn.
  • Fastest growing: India at 11.9% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$79.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Sepsis Diagnostics Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $55.7 Mn — —
2025 (base) $61.1 Mn +$5.4 Mn —
2026 (forecast) $67.1 Mn +$5.9 Mn +9.7%
2027 (forecast) $73.6 Mn +$6.5 Mn +20.3%
2028 (forecast) $80.7 Mn +$7.1 Mn +32%
2029 (forecast) $88.5 Mn +$7.8 Mn +44.8%
2030 (forecast) $97.1 Mn +$8.6 Mn +58.9%
2031 (forecast) $106.5 Mn +$9.4 Mn +74.3%
2032 (forecast) $116.9 Mn +$10.3 Mn +91.2%
2033 (forecast) $128.2 Mn +$11.3 Mn +109.7%
2034 (forecast) $140.6 Mn +$12.4 Mn +130.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Sepsis Diagnostics Market Analysis at a glance
Market size, 2025$61.1 Mn placeholder estimate
Forecast, 2034$140.6 Mn placeholder estimate
Growth (CAGR), 2025–20349.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, biomarker and end user (see all)
Key playersbioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), T2 Biosystems, Prenosis (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials4 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Sepsis Diagnostics Market Analysis Executive Summary

Sepsis diagnostics help doctors spot life-threatening sepsis early and find the germ causing it, using blood tests and biomarkers.

Key segments of the sepsis Diagnostics market include technology (Blood Culture, Molecular Diagnostics and Biomarker Assays) and biomarker (Procalcitonin, Lactate and Monocyte Width).

Bar chart: Japan Sepsis Diagnostics market size, 2024–2034, placeholder estimates. $55.7 Mn in 2024, $61.1 Mn in 2025 and $140.6 Mn in 2034, 9.7% CAGR.
Japan Sepsis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Sepsis Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the sepsis Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the sepsis Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the sepsis Diagnostics market.

Competitive Landscape for Sepsis Diagnostics Market in Japan

The sepsis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Sepsis Diagnostics Market in Japan

Sepsis Diagnostics in Japan: rules, payment and research

Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 4 studies on Sepsis Diagnostics that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how sepsis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Sepsis Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Sepsis Diagnostics in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Sepsis Diagnostics market in Japan?
Placeholder estimate: about $61.1 Mn in 2025, rising to about $140.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sepsis Diagnostics market in Japan growing?
Placeholder estimate: about 9.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sepsis Diagnostics market report cover?
The report splits the market by technology (Blood Culture, Molecular Diagnostics, Biomarker Assays, AI Risk Scores), biomarker (Procalcitonin, Lactate, Monocyte Width) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Sepsis Diagnostics market?
Key players include bioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), T2 Biosystems and Prenosis.
What is driving the Sepsis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the sepsis Diagnostics market.
Who regulates Sepsis Diagnostics in Japan?
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare. Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Sepsis Diagnostics are running in Japan?
4 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Sepsis Diagnostics?
PubMed lists 61 papers on Sepsis Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Japan

See all

Related on diagnostics and lab testing and infectious diseases

See the topic